bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

This study tests a combination of treatments — including a liver procedure (bTAE-HAIC), plus two drugs (lenvatinib and sintilimab) — for people with a particularly advanced form of liver cancer called infiltrative hepatocellular carcinoma. These tumors are large and ill-defined, making them hard to treat with conventional methods. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with infiltrative hepatocellular carcinoma (liver cancer) - Your tumor is large (at least 10 cm) or total tumor burden is at least 15 cm - You have limited or no spread to other organs (up to 5 metastases allowed) - Your liver function is reasonably preserved (Child-Pugh A or B) - Your overall health status is fair (ECOG score 0–1) **You may NOT be eligible if...** - You have major blood vessel invasion beyond certain limits - You have previously received systemic therapy (e.g., sorafenib) - You have serious heart or liver disease beyond the cancer - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.